References
- Lynch TJ , BellDW, SordellaRet al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
- Shaw AT , KimDW, NakagawaKet al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med.368, 2385–2394 (2013).
- Chapman PB , HauschildA, RobertCet al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med.364, 2507–2516 (2011).
- Baselga J , CortesJ, KimSBet al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med.366, 109–119 (2012).
- Gianni L , DafniU, GelberRDet al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol.12, 236–244 (2011).
- Hodi FS , O’DaySJ, McDermottDFet al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363, 711–723 (2010).
- Topalian SL , HodiFS, BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med.366, 2443–2454 (2012).
- Ciardiello F , ArnoldD, CasaliPGet al. Delivering precision medicine in oncology today and in future – the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann. Oncol.25(9), 1673–1678 (2014).
- Garraway LA , VerweijJ, BallmanKV. Precision oncology: an overview. J. Clin. Oncol.31, 1803–1805 (2013).
- Sobrero A , BruzziP. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J. Clin. Oncol.27, 5868–5873 (2009).
- Ellis LM , BernsteinDS, VoestEEet al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol.32(12), 1277–1280 (2014).
- Fojo T , GradyC. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst.101, 1044–1048 (2009).
- Sullivan R , PeppercornJ, SikoraKet al. Delivering affordable cancer care in high-income countries. Lancet Oncol.12, 933–980 (2011).
- Experts in Chronic Myeloid Leukemia . The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood121, 4439–4442, (2013).
- Ou SH , SooRA, KuboAet al. Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-alpha-, NTRK1-) non-small cell lung cancer globally? Front. Oncol. 4, 58 (2014).
- Pignatti F , EhmannF, HemmingsRet al. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European Union. Clin. Cancer Res.20, 1458–1468 (2014).
- Kwak EL , BangYJ, CamidgeDRet al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363, 1693–1703 (2010).
- Malik SM , MaherVE, BijwaardKEet al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin. Cancer Res.20, 2029–2034 (2014).
- Ceritinib gains FDA approval for lung cancer . Cancer Discov.4, 753–754 (2014).
- Shaw AT , KimDW, MehraRet al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med.370, 1189–1197 (2014).
- Chabner BA . Early accelerated approval for highly targeted cancer drugs. N. Engl. J. Med.364, 1087–1089 (2011).
- Chabner BA . Approval after Phase I: ceritinib runs the three-minute mile. Oncologist19, 577–578 (2014).
- Jacobson JO , NeussMN, HauserR. Measuring and improving value of care in oncology practices: ASCO Programs from Quality Oncology Practice Initiative to the Rapid Learning System. Am. Soc. Clin. Oncol. Educ. Book2012, e70–e76 (2012).
- Jagsi R , SulmasyDP, MoyB. Value of cancer care: ethical considerations for the practicing oncologist. Am. Soc. Clin. Oncol. Educ. Book2014, e146–e149 (2014).